Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?

[1]  Leslie L Robison,et al.  Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.

[2]  M. Haigis,et al.  Mitochondria and Cancer , 2016, Cell.

[3]  N. Shapiro,et al.  Mitochondrial Dysfunction, Depleted Purinergic Signaling, and Defective T Cell Vigilance and Immune Defense. , 2016, The Journal of infectious diseases.

[4]  W. Junger,et al.  mTOR and differential activation of mitochondria orchestrate neutrophil chemotaxis , 2015, The Journal of cell biology.

[5]  O. Abdel-Wahab,et al.  Hairy cell leukemia: update and current therapeutic approach , 2015, Current opinion in hematology.

[6]  D Andrews,et al.  Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.

[7]  W. Junger,et al.  Mitochondria Regulate Neutrophil Activation by Generating ATP for Autocrine Purinergic Signaling* , 2014, The Journal of Biological Chemistry.

[8]  W. Junger,et al.  Plasma ATP is Required for Neutrophil Activation in a Mouse Sepsis Model , 2014, Shock.

[9]  N. Shapiro,et al.  Mitochondria Are Gate-keepers of T Cell Function by Producing the ATP That Drives Purinergic Signaling* , 2014, The Journal of Biological Chemistry.

[10]  D. Sabatini,et al.  Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides , 2014, Nature.

[11]  T. Robak,et al.  Older and new purine nucleoside analogs for patients with acute leukemias. , 2013, Cancer treatment reviews.

[12]  L. Antonioli,et al.  Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.

[13]  F. Di Virgilio,et al.  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[14]  A. Ojida,et al.  Organelle-localizable fluorescent chemosensors for site-specific multicolor imaging of nucleoside polyphosphate dynamics in living cells. , 2012, Journal of the American Chemical Society.

[15]  N. Sträter,et al.  Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.

[16]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[17]  S. Devesa,et al.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.

[18]  W. Junger,et al.  Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.

[19]  P. Insel,et al.  Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. , 2010, Blood.

[20]  B. Fredholm,et al.  The birth and postnatal development of purinergic signalling , 2010, Acta physiologica.

[21]  P. Insel,et al.  Autocrine regulation of T‐cell activation by ATP release and P2X7 receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[23]  F. Di Virgilio,et al.  P2X7: a growth-promoting receptor—implications for cancer , 2009, Purinergic Signalling Purinergic Signalling.

[24]  C. Pui.  T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. , 2009, Cancer cell.

[25]  J. Buer,et al.  Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels , 2008, Science Signaling.

[26]  F. Di Virgilio,et al.  Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.

[27]  P. Insel,et al.  HYPERTONIC STRESS REGULATES T-CELL FUNCTION BY THE OPPOSING ACTIONS OF EXTRACELLULAR ADENOSINE TRIPHOSPHATE AND ADENOSINE , 2007, Shock.

[28]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[29]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[30]  S. Jalkanen,et al.  The detection of micromolar pericellular ATP pool on lymphocyte surface by using lymphoid ecto-adenylate kinase as intrinsic ATP sensor. , 2006, Molecular biology of the cell.

[31]  G. Burnstock,et al.  P2 receptors and cancer. , 2006, Trends in pharmacological sciences.

[32]  Xiao-tong Ma,et al.  Expression of P2X7 in human hematopoietic cell lines and leukemia patients. , 2004, Leukemia research.

[33]  M. Poot,et al.  Efficacy of MitoTracker Green™ and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[34]  M. Guppy,et al.  Cancer metabolism: facts, fantasy, and fiction. , 2004, Biochemical and biophysical research communications.

[35]  F. Di Virgilio,et al.  P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. , 2002, Blood.

[36]  F. Meyers,et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Steinkamp,et al.  Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. , 2000, Cytometry.

[38]  F. Di Virgilio,et al.  Increased Proliferation Rate of Lymphoid Cells Transfected with the P2X7 ATP Receptor* , 1999, The Journal of Biological Chemistry.

[39]  N. Sriranganathan,et al.  A dye-based lymphocyte proliferation assay that permits multiple immunological analyses: mRNA, cytogenetic, apoptosis, and immunophenotyping studies. , 1997, Journal of immunological methods.

[40]  M. R. Cooper,et al.  Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.

[41]  O. Sartor,et al.  Acute renal toxicity associated with suramin in the treatment of prostate cancer , 1994, Cancer.

[42]  J. Wilting,et al.  Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.

[43]  C. Taylor,et al.  Effects of suramin on in vitro growth of fresh human tumors. , 1992, Journal of the National Cancer Institute.

[44]  W. Linehan,et al.  Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.

[45]  M. Sitkovsky,et al.  Extracellular ATP in T-lymphocyte activation: possible role in effector functions. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Pollak,et al.  Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. , 1990, Journal of the National Cancer Institute.

[47]  J. Fitchen,et al.  Purine metabolism as a target for leukemia chemotherapy. , 1989, Blood reviews.

[48]  G. Reaman,et al.  Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. , 1981, Cancer research.

[49]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[50]  S. Weinberg,et al.  Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.

[51]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[52]  Geoffrey Burnstock,et al.  Purinergic signalling , 2012, Acta physiologica.

[53]  G. Giaccone,et al.  Effects of suramin on human lung cancer cell lines. , 1995, European Journal of Cancer.

[54]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[55]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.